Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

469
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
469
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

301
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
301
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

575
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
575
Drug Therapy01:28

Drug Therapy

134
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
134
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

463
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
463
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

631
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.

Frontiers in psychiatry·2024
Same author

Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation.

Molecular psychiatry·2024
Same author

Early life adversities, psychopathologies and novel pharmacological strategies.

Pharmacology & therapeutics·2024
Same author

The complex scenario behind the term antipsychotic drug.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2023
Same author

Bdnf-Nrf-2 crosstalk and emotional behavior are disrupted in a sex-dependent fashion in adolescent mice exposed to maternal stress or maternal obesity.

Translational psychiatry·2023
Same author

The Natural Protoalkaloid Methyl-2-Amino-3-Methoxybenzoate (MAM) Alleviates Positive as well as Cognitive Symptoms in Rat and Mouse Schizophrenia Models.

Current neuropharmacology·2023
Same journal

Femicide is a crime of power: learning a new vocabulary.

Rivista di psichiatria·2026
Same journal

The absolute possess. A psychoanalytic reading of femicide.

Rivista di psichiatria·2026
Same journal

Mental disorder and criminal responsibility in femicide: a cross-jurisdictional analysis.

Rivista di psichiatria·2026
Same journal

Psychopathological profiles of femicide and femicide-suicide: from a descriptive analysis to a possible structural model.

Rivista di psichiatria·2026
Same journal

Homicide-suicide: current evidence, risk assessment, and medico-legal implications in forensic psychiatry.

Rivista di psichiatria·2026
Same journal

Femicide as the extreme expression of violence against women: medico-legal definition, forensic evidence and prevention perspectives from an Italian nationwide study.

Rivista di psichiatria·2026
See all related articles

Related Experiment Video

Updated: Nov 5, 2025

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

361

[Third-generation antipsychotics: focus on cariprazine].

Marco A Riva1

  • 1Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano - IRCCS Fatebenefratelli, San Giovanni di Dio, Brescia.

Rivista Di Psichiatria
|May 18, 2021
PubMed
Summary
This summary is machine-generated.

Cariprazine, a novel antipsychotic, shows promise for schizophrenia treatment by stabilizing dopamine function, particularly through its D3 receptor partial agonism, potentially improving negative and cognitive symptoms.

More Related Videos

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

1.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K

Related Experiment Videos

Last Updated: Nov 5, 2025

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

361
Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

1.8K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K

Area of Science:

  • Neuroscience
  • Psychopharmacology
  • Schizophrenia Research

Background:

  • Antipsychotic drugs are crucial for schizophrenia treatment but exhibit diverse mechanisms.
  • Critical issues in schizophrenia management necessitate innovative pharmacological approaches.

Purpose of the Study:

  • To review critical issues in schizophrenia treatment.
  • To explore the pharmacological innovation of D2/D3 receptor partial agonists.
  • To detail the receptor and functional mechanisms of cariprazine.

Main Methods:

  • Review of existing literature on antipsychotic drugs and schizophrenia treatment.
  • Focus on partial agonists for dopamine D2 and D3 receptors.
  • Analysis of cariprazine's specific receptor binding profile and functional effects.

Main Results:

  • Cariprazine exhibits greater affinity for the dopaminergic D3 receptor compared to other agents.
  • Its dominant D3 partial agonism is linked to improvements in negative symptoms and motivational deficits.
  • Cariprazine's receptor profile may also benefit cognitive deficits and co-occurring substance abuse.

Conclusions:

  • Cariprazine represents a significant pharmacological innovation in antipsychotic therapy.
  • Its unique D3 receptor activity offers a potential strategy for stabilizing dopaminergic function in schizophrenia.
  • The drug's mechanism may address core functional domains altered in schizophrenia, including negative, cognitive, and substance use issues.